Shares of Lupin Ltd dropped the most in more than six-and-a-half years after the drugmaker said the US regulator issued a combined warning letter for its Goa and Indore-Unit II plants, a move that may delay future drug approvals.
A warning letter is issued by the US Food and Drug Administration if it finds a manufacturer or any other organisation has violated a regulated activity.
Lupin earlier received three Form-483 observations for the Goa plant on 7 April and six for its Indore unit on 18 May after inspections. The company said it had responded to all observations and was “deeply disappointed at the FDA outcome.”
Shares of Lupin dropped as much as 17.9 percent to their lowest since 26 November 2013 after it informed the exchanges. While the company does not expect disruption of existing product supplies, it said a delay is likely in new product approvals from the two facilities.
Both the plants together contribute more than half of the drugmaker's US sales and approximately 20 percent of its total sales, Surajit Pal, pharma analyst, Prabhudas Lilladher, said.
Don’t see an immediate impact on earnings as existing products can be sold. Issue will be with pipeline that will now get affected.Surajit Pal, pharma analyst, Prabhudas Lilladher
Amey Chalke, a pharma analyst at HDFC Securities, expects a significant cut in earnings estimate for Lupin. “The warning letter will mean future approvals will be halted. It will be difficult for Lupin to offset the slowdown in Glumetza and Fortamet with this move,” he told BloombergQuint over the phone.
(This article was originally published in BloombergQuint)
(Breathe In, Breathe Out: Are you finding it tough to breathe polluted air? Join hands with FIT to find #PollutionKaSolution. Send in your suggestions to fit@thequint.com or WhatsApp @+919999008335)
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)